Foresee Pharmaceuticals announces the Casppian Phase 3 Study Meets Primary Efficacy Endpoint, Demonstrating Robust LH Suppression with 6-Month Dosing Interval of leuprolide ...

FP-001 42 mg is an investigational, sustained-release formulation of a GnRH agonist being developed for the treatment of CPP. It is designed to provide continuous suppression of gonadotropin secretion ...
Nasdaq

Veru Enrolls First Patient in Phase 2 Clinical Trial of VERU-100, Novel Long-acting GnRH Antagonist Decapeptide Injection Formulation, for the Treatment of Hormone Sensitive ...

MIAMI, June 10, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, ...
Business Insider

ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy

- OBE2109 is a GnRH receptor antagonist currently in development as both a stand-alone treatment and with add-back therapy designed to address the needs of endometriosis and uterine fibroid patients - ...
Renal & Urology News

GnRH Antagonist vs Agonist for Metastatic Prostate Cancer Tied With Lower Mortality

Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...